Arthrobotrys oligospora doesn’t live a charmed life; it survives on a diet of roundworm.
Nanotechnology developed by Delaware scientists could potentially deliver chemotherapy to children in a way that attacks cancer cells without harming healthy cells, greatly reducing side effects.
FoodChek Systems Inc. ("FoodChek" or the "Corporation") is very proud to announce that the AOAC Research Institute, the approval body for all U.S. food safety tests, has validated and certified as a Performance Tested Method ("PTM"), FoodChek's patent pending Actero™ Listeria Enrichment Media (License #111201) and the FoodChek™ Listeria spp. Assay Cassette (License #111202).
Genisphere and the nonprofit Lankenau Institute for Medical Research (LIMR), which are already making progress together on identifying Inflammatory Bowel Disease biomarkers, have partnered to develop nanotherapeutics targeting cancers and eye diseases.
With headlines filled with global turmoil, it is always refreshing to see that, within the realm of biomedical research, national boundaries are being successfully transcended, paving the way for a truly worldwide effort to improve lives.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, today announced that it has entered into a strategic global collaboration with Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies.
Many people are concerned with changes in their body shape as they age. Changes related to the aging process cause structural transformation of proteins in deep layers of the skin, promoting skin dryness, reduction of skin thickness, papery look, sagginess and other typical for aging processes symptoms. The best solution is to prevent and slow down the skin structural changes.
Mentor Capital, Inc. announced it has executed a Letter of Intent with Nanovega, Inc. for $6 million to fund the production scale up of its ultra-small synthetic antibodies. These nano-scale molecules are approximately one-tenth the size of most alternative cancer delivery bio-markers. The small size allows the nano-bodies to slip throughout solid tumors instead of piling up at the surface as is often currently encountered in cancer treatment.
A medical researcher with the University of Alberta and his team just published their findings about their work on developing 'homing beacon drugs' that kill only cancer cells, not healthy ones, thanks to nano-technology.
Researchers at Wake Forest Baptist Medical Center have modified electrically-conductive polymers, commonly used in solar energy applications, to develop revolutionary polymer nanoparticles (PNs) for a medical application. When the nanoparticles are exposed to infrared light, they generate heat that can be used to kill colorectal cancer cells.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.